In a G&D paper published online ahead of its April 1 print publication date, Dr. William Kaelin (Dana Farber Cancer Institute) and colleagues identify a potential new neuronal tumor suppressor.
“It has been suspected for decades that the short arm of chromosome 1 harbored one or more tumor suppressor genes because this region is deleted in a variety of tumors, including many neural crest-derived tumors. Our work suggests that KIFB{beta} is one such gene,” explains Dr. Kaelin.
Neural crest-derived tumors include neuroblastomas and medulloblastomas, which are the most common malignant pediatric solid tumors, as well as paragangliomas (relatively rare tumors of the sympathetic nervous system) and melanomas, the deadliest form of skin cancer.
Under normal developmental conditions, neural crest cells respond to diminishing growth factor signaling by inducing apoptosis, via a pathway involving the enzyme EglN3. However, the acquisition of mutations that enable cells to avoid apoptosis under low growth factor conditions provide a growth advantage and an effective route to tumorigenesis.
In this issue, Dr. Kaelin and colleagues identify that the protein KIF1B{beta} mediates EglN3-induced neuronal apoptosis, and thus provides a protective effect against the development of neural crest-derived tumors.
Importantly, KIF1B{beta} is positioned on the region of chromosome 1p that is deleted in a number of neural crest-derived tumors. The Kaelin group demonstrated that the supplementation of 1p-deleted neuroblastoma cancer cells with KIF1B{beta} protein is sufficient to restore apoptosis and identified inactivating point mutations in neural crest-derived tumors. They also showed that partial reduction of KIF1B{beta} - but not complete loss - confers protection against apoptosis, perhaps explaining why most 1p deleted tumors still retain the other KIF1B{beta} allele in its normal form.
While further research is needed to delineate the mechanism by which KIF1B{beta} induces apoptosis, this work opens up several avenues for investigation. For example, EglN3 is an oxygen-dependent enzyme that responds to a variety of signals and can be modulated with drug-like molecules. Dr. Kaelin points out that “an intriguing possibility is that an increase in EglN3 activity is responsible for the spontaneous regressions frequently observed in neonates who present with Neuroblastoma (so-called Stage 4S Neuroblastoma). Perhaps, in time, we can mimic this with EglN3 agonists.”
Source: Cold Spring Harbor Laboratory
Related stories:
Nerve cells derived from stem cells and transplanted into mice may lead to improved brain treatments
Scientists at the Burnham Institute for Medical Research have, for the first time, genetically programmed embryonic stem (ES) cells to become nerve cells when transplanted into the brain, according to a study published today in
The Journal of Neuroscience. The research, an important step toward developing new treatments for stroke, Alzheimer's, Parkinson's and other neurological conditions showed that mice afflicted by stroke showed tangible therapeutic improvement following transplantation of these cells. None of the mice formed tumors, which had been a major setback in prior attempts at stem cell transplantation.
Blue light used to harden tooth fillings stunts tumor growth
A blue curing light used to harden dental fillings also may stunt tumor growth, Medical College of Georgia researchers say.
Stem cell researchers give old muscle new pep
Old muscle got a shot of youthful vigor in a stem cell experiment by bioengineers at the University of California, Berkeley, setting the path for research on new treatments for age-related degenerative conditions such as muscle atrophy or Alzheimer's and Parkinson's diseases.
Overcoming Drug Resistance—Nanoparticles Trigger Built-In Cell-Death Signal
One of the most vexing problems in treating cancer is the propensity of tumors to develop resistance to a wide range of anticancer drugs. Over 70 percent of ovarian cancer patients, for example, have drug-resistant tumors at the time of their initial diagnosis, and virtually all patients who relapse have drug-resistant tumors.
Researchers show how the brain can protect against cancer
Scientists have been aware for many years that if cancer patients are not able to deal with the stress associated with being sick, the cancer will progress faster than in calmer patients. To counteract this phenomenon, physicians encourage treatments that help cancer patients handle their stress. Scientists theorized that the stress relief may have come as a result of increased beta-endorphin peptide (BEP), the "feel good" hormones in the brain that are released during exercise, a good conversation, and many other aspects of life that give humans pleasure.
Caution on stem cell therapy
A single organ may contain more than one type of adult stem cell – a discovery that complicates prospects for using the versatile cells to replace damaged tissue as a treatment for disease, according to a new study from the laboratory of geneticist Mario Capecchi, the University of Utah's Nobel Laureate.
Synthetic molecules hold promise for new family of anti-cancer drugs
Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue.
Fruits, vegetables and teas may protect smokers from lung cancer
Tobacco smokers who eat three servings of fruits and vegetables per day and drink green or black tea may be protecting themselves from lung cancer, according to a first-of-its-kind study by UCLA cancer researchers.